Niraparib as Maintenance Treatment in Platinum Responsive Ovarian Cancer Patients: a Real Life Study
NCT04617470 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300
Last updated 2021-08-25
Summary
This is an observational phase IV study evaluating Niraparib as maintenance treatment in patients with platinum sensitive, platinum responsive, recurrent ovarian cancer in a real life setting.
Conditions
Sponsors & Collaborators
- collaborator INDUSTRY
-
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
lead OTHER
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-07-08
- Primary Completion
- 2022-01-01
- Completion
- 2022-01-01
Countries
- Italy
Study Locations
More Related Trials
-
Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer
NCT04986371 ·Status: UNKNOWN
-
Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer
NCT03759587 ·Status: COMPLETED ·Phase: PHASE2
-
MITO-6: Capecitabine in Platinum Resistant Ovarian Cancer
NCT00403429 ·Status: COMPLETED ·Phase: PHASE2
-
A Real-World Patient-Reported Outcomes Study in Patients With Long-Term Use of Niraparib
NCT06037213 ·Status: UNKNOWN
-
MITO 35B: Olaparib Beyond Progression Compared to Platinum Chemotherapy After Secondary Cytoreductive Surgery in Recurrent Ovarian Cancer Patients.
NCT05255471 ·Status: RECRUITING ·Phase: PHASE3
-
Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer
NCT03598270 ·Status: COMPLETED ·Phase: PHASE3
-
Niraparib Maintenance Treatment in Patients With Newly Diagnosed Advanced Platinum- Sensitive, OC. The First Poland RWE Study.
NCT06614790 ·Status: RECRUITING
-
Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.
NCT03467178 ·Status: UNKNOWN ·Phase: PHASE2
-
Effectiveness and Safety of Niraparib as First-line Maintenance Therapy for Ovarian Cancer: a Real-world Study
NCT05734911 ·Status: COMPLETED
-
Niraparib Plus Anlotinib for Recurrent Ovarian Cancer
NCT05311579 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
NCT01482715 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study of Niraparib in Patients With Relapsed Ovarian Cancer
NCT04392102 ·Status: COMPLETED ·Phase: PHASE2
-
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
NCT04507841 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer
NCT04546373 ·Status: COMPLETED
-
NIRAPK : Study of the Relationship(s) Between Clinical, Biological and Pharmacokinetic Metrics and Toxicities When Niraparib is Used as Maintenance Treatment for Ovarian Cancer Patients.
NCT04861181 ·Status: TERMINATED ·Phase: PHASE4
-
Alternative Dosing Of Niraparib To Decrease Dose Interruption In First Line Maintenance Treatment For Ovarian Cancer
NCT05961124 ·Status: RECRUITING ·Phase: PHASE2
-
Niraparib Maintenance in HRD-Positive Advanced Ovarian Cancer Following Front-Line Chemotherapy + Bevacizumab
NCT06141265 ·Status: RECRUITING ·Phase: PHASE2
-
Niraparib and Bevacizumab Maintenance Therapy in Platinum-sensitive Recurrent Ovarian Cancer Patients Previously Treated With a PARP Inhibitor
NCT04734665 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety of Niraparib Combined With Bevacizumab in Platinum Refractory/Resistant Recurrent Ovarian Cancer
NCT04556071 ·Status: UNKNOWN ·Phase: PHASE2
-
Study on MK-3475 Plus Chemotherapy Versus Chemotherapy Alone in Recurrent, Platinum-resistant Ovarian Cancer
NCT03539328 ·Status: UNKNOWN ·Phase: PHASE2
-
Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed Non gBRCAm Ovarian Cancer Patients
NCT03402841 ·Status: COMPLETED ·Phase: PHASE3
-
Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer
NCT03759600 ·Status: COMPLETED ·Phase: PHASE2
-
Anlotinib and Niraparib Dual Therapy Evaluation in Platinum-resistant Recurrent Ovarian Cancer
NCT04376073 ·Status: UNKNOWN ·Phase: PHASE2
-
PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer
NCT05187208 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4